Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters

Rucker, 2018, Psychiatry & the psychedelic drugs. Past, present & future, Neuropharmacology., 142, 200, 10.1016/j.neuropharm.2017.12.040 Fischer, 2021, Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial, Neuropsychopharmacology., 46, 809, 10.1038/s41386-020-00905-3 Mehta, 2019, Serotonin and the psychedelics, 193 Canal, 2018, Serotonergic psychedelics: Experimental approaches for assessing mechanisms of action, 227, 10.1007/164_2018_107 Patocka, 2021, Chemistry and toxicology of major bioactive substances in inocybe mushrooms, Int. J. Mol. Sci., 22, 2218, 10.3390/ijms22042218 Musshoff, 2000, Hallucinogenic mushrooms on the German market—simple instructions for examination and identification, Forensic Sci. Int., 113, 389, 10.1016/S0379-0738(00)00211-5 Rutter, 1996, Psilocybin mushrooms of the world : an identification guide, Edinb. J. Bot., 56, 245 McKenna, 2018, 36, 283 N. USDA Shulgin, 1997 Strassman, 1996, Human psychopharmacology of N, N-dimethyltryptamine, Behav. Brain Res., 73, 121, 10.1016/0166-4328(96)00081-2 Grella, 1998, Investigation of hallucinogenic and related β-carbolines, Drug Alcohol Depend., 50, 99, 10.1016/S0376-8716(97)00163-4 Barabasz-Gembczyk, 2020, undefined 2020, Ayahuasca–potential therapeutic properties in psychiatry. Research review, Psychiatriapolska.Pl., 54, 381 Gable, 2007, Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids, Addiction., 102, 24, 10.1111/j.1360-0443.2006.01652.x Simão, 2020, Determination of N,N-dimethyltryptamine and beta-carbolines in plants used to prepare ayahuasca beverages by means of solid-phase extraction and gas-chromatography–mass spectrometry, SN Appl. Sci., 2, 1, 10.1007/s42452-020-2296-0 Drucker, 1990, Dopamine uptake inhibitory capacities of β-carboline and 3, 4-dihydro-β-carboline analogs of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) oxidation, Brain Res., 509, 125, 10.1016/0006-8993(90)90318-6 Brito, 1996, Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil, J. Nerv. Ment. Dis., 184, 86, 10.1097/00005053-199602000-00004 McKenna, 1984, Monoamine oxidase inhibitors in south American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca, J. Ethnopharmacol., 10, 195, 10.1016/0378-8741(84)90003-5 Halpern, 2004, Hallucinogens and dissociative agents naturally growing in the United States, Pharmacol. Ther., 10.1016/j.pharmthera.2004.03.003 Voynova, 2020, Toxicological and pharmacological profile of Amanita muscaria (L.) Lam.–a new rising opportunity for biomedicine, Pharmacia., 67, 317, 10.3897/pharmacia.67.e56112 Shulgin, 1979, Chemistry of phenethylamines related to mescaline, J. Psychoactive Drugs, 11, 41 Schep, 2016, Ibogaine for treating drug dependence. What is a safe dose?, Drug Alcohol Depend., 166, 1, 10.1016/j.drugalcdep.2016.07.005 Alper, 2012, Fatalities temporally associated with the ingestion of ibogaine, J. Forensic Sci., 57, 398, 10.1111/j.1556-4029.2011.02008.x Rodrĺguez, 2020, A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats, ACS Chem. Neurosci., 11, 1661, 10.1021/acschemneuro.0c00152 Brown, 2018, Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes, Am. J. Drug Alcohol Abuse., 44, 24, 10.1080/00952990.2017.1320802 Mash, 2000, Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures, Ann. N. Y. Acad. Sci., 914, 394, 10.1111/j.1749-6632.2000.tb05213.x Carbonaro, 2015, The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice, Psychopharmacology, 232, 275, 10.1007/s00213-014-3658-3 Valle, 2016, Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans, Eur. Neuropsychopharmacol., 26, 1161, 10.1016/j.euroneuro.2016.03.012 Palhano-Fontes, 2018, Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial, Psychol. Med., 49, 655, 10.1017/S0033291718001356 Jiménez-Garrido, 2020, Effects of ayahuasca on mental health and quality of life in naïve users: a longitudinal and cross-sectional study combination, Nature, Com., 2020 Carlos Bouso, 2015, Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans, Eur. Neuropsychopharmacol., 25, 483, 10.1016/j.euroneuro.2015.01.008 Cameron, 2018, Effects of N, N-dimethyltryptamine on rat behaviors relevant to anxiety and depression, ACS Chem. Neurosci., 9, 1582, 10.1021/acschemneuro.8b00134 Haberzettl, 2013, Animal models of the serotonin syndrome: a systematic review, Behav. Brain Res., 256, 328, 10.1016/j.bbr.2013.08.045 Aghajanian, 1970, Action of psychotogenic drugs on single midbrain raphe neurons, J. Pharmacol. Exp. Ther., 171, 178 Morales-Garcia, 2020, N, N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo, Transl. Psychiatry, 10, 1, 10.1038/s41398-020-01011-0 Ray, 2010, Psychedelics and the human receptorome, PLoS One, 5, 10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 Smith, 1998, Agonist properties of N, N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors, Pharmacol. Biochem. Behav., 61, 322, 10.1016/S0091-3057(98)00110-5 Strassman, 1996, Differential tolerance to biological and subjective effects of four closely spaced doses of N, N-dimethyltryptamine in humans, Biol. Psychiatry, 39, 784, 10.1016/0006-3223(95)00200-6 Szabo, 2014, Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells, PLoS One, 9, 10.1371/journal.pone.0106533 Blough, 2014, Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes, Psychopharmacology, 231, 4135, 10.1007/s00213-014-3557-7 Shen, 2010, Psychedelic 5-methoxy-N, N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions, Curr. Drug Metab., 11, 659, 10.2174/138920010794233495 Rickli, 2016 Berge, 1983, Inhibitory effect of 5-methoxy-N, N-dimethyltryptamine on the synaptosomal uptake of 5-hydroxytryptamine, Eur. J. Pharmacol., 90, 293, 10.1016/0014-2999(83)90253-4 Cipriani, 2018, Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Focus (Madison)., 16, 420, 10.1176/appi.focus.16407 Cozzi, 2009, Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter, J. Neural Transm., 116, 1591, 10.1007/s00702-009-0308-8 Andersen, 2014, Molecular basis for selective serotonin reuptake inhibition by the antidepressant agent fluoxetine (Prozac), Mol. Pharmacol., 85, 703, 10.1124/mol.113.091249 de Castro-Neto, 2013, Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion, World J. Biol. Chem., 4, 141, 10.4331/wjbc.v4.i4.141 Schoueri Colaço, 2020, Toxicity of ayahuasca after 28 days daily exposure and effects on monoamines and brain-derived neurotrophic factor (BDNF) in brain of Wistar rats, Metab. Brain Dis., 35, 739, 10.1007/s11011-020-00547-w Nichols, 2014, N-Benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues, ACS Chem. Neurosci., 6, 1165, 10.1021/cn500292d Jiménez, 2022, Significance of mammalian N, N-dimethyltryptamine (DMT): a 60-year-old debate, J. Psychopharmacol., 36, 905, 10.1177/02698811221104054 Berry, 2017, Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges, Pharmacol. Ther., 1, 161, 10.1016/j.pharmthera.2017.07.002 Hamill, 2019, Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness, Curr. Neuropharmacol., 17, 108, 10.2174/1570159X16666180125095902 Langer, 1984, Possible endocrine role of the pineal gland for 6-methoxytetrahydro-β-carboline, a putative endogenous neuromodulator of the [3H] imipramine recognition site, Eur. J. Pharmacol., 102, 379, 10.1016/0014-2999(84)90275-9 Cumming, 2021, Molecular and functional imaging studies of psychedelic drug action in animals and humans, Molecules., 26, 2451, 10.3390/molecules26092451 Jiang, 2019, Mechanism-based pharmacokinetics-pharmacodynamics studies of harmine and harmaline on neurotransmitters regulatory effects in healthy rats: challenge on, Phytomedicine., 62, 10.1016/j.phymed.2019.152967 Brierley, 2013, Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell, J. Psychopharmacol., 27, 98, 10.1177/0269881112463125 Hibicke, 2020, Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression, ACS Appl. Mater. Interfaces, 11, 864 Chadeayne, 2020, Active metabolite of aeruginascin (4-hydroxy-N,N,N-trimethyltryptamine): synthesis, structure, and serotonergic binding affinity, ACS Publ., 5, 16940 Aghajanian Shuto, 2020, Obligatory roles of dopamine D1 receptors in the dentate gyrus in antidepressant actions of a selective serotonin reuptake inhibitor, fluoxetine, Mol. Psychiatry, 25, 1229, 10.1038/s41380-018-0316-x Guiard, 2008, Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions, Int. J. Neuropsychopharmacol., 11, 625, 10.1017/S1461145707008383 Dremencov, 2009, Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area, J. Psychiatry Neurosci., 34, 223 Santana, 2013, Expression of α1-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT2A receptors, Int. J. Neuropsychopharmacol., 16, 1139, 10.1017/S1461145712001083 Vollenweider, 1999, 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with raclopride, Neuropsychopharmacology., 20, 424, 10.1016/S0893-133X(98)00108-0 Passie, 2002, The pharmacology of psilocybin, Addict. Biol., 7, 357, 10.1080/1355621021000005937 Winter, 2007, Psilocybin-induced stimulus control in the rat, Pharmacol. Biochem. Behav., 87, 472, 10.1016/j.pbb.2007.06.003 Madsen, 2019, Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels, Neuropsychopharmacology., 44, 1328, 10.1038/s41386-019-0324-9 Wade, 2008, Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses, J. Neurosci., 28, 6508, 10.1523/JNEUROSCI.0678-08.2008 Kometer, 2012, Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors, Biol. Psychiatry, 72, 898, 10.1016/j.biopsych.2012.04.005 Hesselgrave, 2021, Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice, Proc. Natl. Acad. Sci., 118, 10.1073/pnas.2022489118 Rickli, 2016, Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens, Eur. Neuropsychopharmacol., 26, 1327, 10.1016/j.euroneuro.2016.05.001 Wankhar, 2020, Effect of 5-HT2C receptor agonist and antagonist on chronic unpredictable stress (CUS)-mediated anxiety and depression in adolescent Wistar albino rat: implicating, Behav. Brain Res., 393, 10.1016/j.bbr.2020.112780 Halberstadt, 2011, Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice, J. Psychopharmacol., 25, 1548, 10.1177/0269881110388326 Dos Santos, 2019, Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer, BMC Psychiatry., 19, 1, 10.1186/s12888-019-2288-z Flanagan, 2022, Psychedelics and anti-inflammatory activity in animal models, 229 Mason, 2022, 2010 Halberstadt, 2018, Effect of hallucinogens on unconditioned behavior, Curr. Top. Behav. Neurosci., 36, 159, 10.1007/7854_2016_466 Carter, 2005, Using psilocybin to investigate the relationship between attention, working memory and the serotonin 5-HT1A and 5-HT2A receptors, J. Cogn. Neurosci., 17, 1497, 10.1162/089892905774597191 Canal, 2018, Serotonergic psychedelics: experimental approaches for assessing mechanisms of action, Handb. Exp. Pharmacol., 252, 227, 10.1007/164_2018_107 Vollenweider, 2001, Brain mechanisms of hallucinogens and entactogens, Dialogues Clin. Neurosci., 3, 265, 10.31887/DCNS.2001.3.4/fxvollenweider Muller, 2020, Serotonin and schizophrenia, 711 Gellman, 1994, Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs, Neuroscience., 58, 515, 10.1016/0306-4522(94)90077-9 Jacobs, 2007, Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter, J. Biol. Chem., 282, 29441, 10.1074/jbc.M704456200 Cameron, 2021, A non-hallucinogenic psychedelic analogue with therapeutic potential, Nature., 589, 474, 10.1038/s41586-020-3008-z Bulling, 2012, The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters, J. Biol. Chem., 287, 18524, 10.1074/jbc.M112.343681 Coleman, 2019, Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport, Nature., 569, 141, 10.1038/s41586-019-1135-1 Baumann, 2001, In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats, J. Pharmacol. Exp. Ther., 297, 531 Marton, 2019, Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits, Front. Pharmacol., 10, 193, 10.3389/fphar.2019.00193 Thompson, 2021, Optimizing psychedelic compounds for neuropsychiatric therapy, Neuropsychopharmacology., 46, 1397, 10.1038/s41386-021-01004-7 Pottie, 2019, Anal. Chem., 91, 15444, 10.1021/acs.analchem.9b03104 Kovacic, 2009, Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure, Oxidative Med. Cell. Longev., 2, 181, 10.4161/oxim.2.4.9380 Dinis-Oliveira, 2019, Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions, Curr. Mol. Pharmacol., 12, 184, 10.2174/1874467211666181010154139 Tilson, 1972, Studies on the concurrent behavioral and neurochemical effects of psychoactive drugs using the push-pull cannula, J. Pharmacol. Exp. Ther., 181, 387 Agin-Liebes, 2021, Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes, ACS Pharmacol. Transl. Sci., 4, 543, 10.1021/acsptsci.1c00018 Trulson, 1983, Mescaline elicits behavioral effects in cats by an action at both serotonin and dopamine receptors, Eur. J. Pharmacol., 96, 151, 10.1016/0014-2999(83)90544-7 Freedman, 1970, Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism, Biochem. Pharmacol., 19, 1181, 10.1016/0006-2952(70)90378-3 König-Bersin, 1970, Monoamines in the brain under the influence of muscimol and ibotenic acid, two psychoactive principles of Amanita muscaria, Psychopharmacologia., 18, 1, 10.1007/BF00402378 Palhano-Fontes, 2015, The psychedelic state induced by Ayahuasca modulates the activity and connectivity of the default mode network, PLoS One, 10, 10.1371/journal.pone.0118143 Vollenweider, 2010, The neurobiology of psychedelic drugs: implications for the treatment of mood disorders, Nat. Rev. Neurosci., 11, 642, 10.1038/nrn2884 Vollenweider, 1998, Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action, Neuroreport., 9, 3897, 10.1097/00001756-199812010-00024 Dakic, 2017, Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT, Sci. Rep., 7, 1, 10.1038/s41598-017-12779-5 Riga, 2014, The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs, Int. J. Neuropsychopharmacol., 17, 1269, 10.1017/S1461145714000261 Murphy-Beiner, 2020, Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers, Psychopharmacology, 237, 1161, 10.1007/s00213-019-05445-3 Li, 2011, Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression, Neuropharmacology., 60, 1168, 10.1016/j.neuropharm.2010.10.016 Mahmoudi, 2018, Alteration of depressive-like behaviors by Psilocybe cubensis alkaloid extract in mice: the role of glutamate pathway, Res. J. Pharmacogn., 5, 17 Martín-Ruiz, 2001, Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism, J. Neurosci., 21, 9856, 10.1523/JNEUROSCI.21-24-09856.2001 Carhart-Harris, 2012, Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin, Proc. Natl. Acad. Sci. U. S. A., 109, 2138, 10.1073/pnas.1119598109 Ling, 2022, Molecular mechanisms of psilocybin and implications for the treatment of depression, CNS Drugs., 36, 17, 10.1007/s40263-021-00877-y Saha, 2023, The crosstalk between 5-HT2AR and mGluR2 in schizophrenia, Neuropharmacology., 109489 Marek, 2018, Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons, Behav. Neurobiol. Psychedelic Drugs., 36, 107, 10.1007/7854_2017_480 Alper, 2001 Aghajanian, 1999, Serotonin–glutamate interactions: a new target for antipsychotic drugs, Neuropsychopharmacology., 21, 122, 10.1016/S0893-133X(99)00106-2 Gewirtz, 2000, Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors, Neuropsychopharmacology., 23, 569, 10.1016/S0893-133X(00)00136-6 McCall, 1980, Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus, Life Sci., 26, 1149, 10.1016/0024-3205(80)90654-2 Waldmeier, 1977, Neurochemical investigations of the interaction of N,N-dimethyltryptamine with the dopaminergic system in rat brain, Psychopharmacology, 52, 137, 10.1007/BF00439100 Miralles, 2005, High affinity binding of β-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA, Eur. J. Pharmacol., 518, 234, 10.1016/j.ejphar.2005.06.023 Archer, 1993, Blockade and reversal of 5-methoxy-N, N-dimethyltryptamine-induced analgesia following noradrenaline depletion, Brain Res., 333, 55, 10.1016/0006-8993(85)90123-4 Fuxe, 1972, Effects of 5-methoxy-N, N-dimethyltryptamine on central monoamine neurons, Eur. J. Pharmacol., 19, 25, 10.1016/0014-2999(72)90073-8 Marona-Lewicka, 1995, Complex stimulus properties of LSD: a drug discrimination study with α2-adrenoceptor agonists and antagonists, Psychopharmacology, 120, 384, 10.1007/BF02245809 Herblin, 1968, Interactions of norepinephrine with subcellular fractions of rat brain I. Characteristics of norepinephrine uptake, Brain Res., 8, 298, 10.1016/0006-8993(68)90050-4 Aghajanian, 1980, Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli, Brain Res., 186, 492, 10.1016/0006-8993(80)90997-X Smith, 1977, Increased synthesis of striatal dopamine by N, N-dimethyltryptamine, Life Sci., 21, 1597, 10.1016/0024-3205(77)90236-3 Waldmeier, 1976, Preferential deamination of dopamine by an a type monoamine oxidase in rat brain, Naunyn. Schmiedebergs, Arch. Pharmacol., 292, 9, 10.1007/BF00506483 Haubrich, 1977, N-dimethyltryptamine lowers rat brain acetylcholine and dopamine, Brain Res., 131, 158, 10.1016/0006-8993(77)90036-1 Sambo, 2018, The sigma-1 receptor as a regulator of dopamine neurotransmission: a potential therapeutic target for methamphetamine addiction, Pharmacol. Ther., 186, 152, 10.1016/j.pharmthera.2018.01.009 Sambo, 2017, The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission, Nat. Commun., 8, 1, 10.1038/s41467-017-02087-x Marek, 1996, LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex, J. Pharmacol. Exp. Ther., 278, 1373 Inserra, 2018, Hypothesis: the psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process, Front. Pharmacol., 330, 10.3389/fphar.2018.00330 Liester, 2012, Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions, J. Psychoactive Drugs, 44, 200, 10.1080/02791072.2012.704590 Farzin, 2008, Antidepressant-like effect of harmane and other B-carbolines in the mouse forced swim test, Int. J. Neuropsychopharmacol., 11, 126 Borbély, 2022, Novel drug developmental strategies for treatment-resistant depression, Br. J. Pharmacol., 179, 1146, 10.1111/bph.15753